Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00897754
First received: May 9, 2009
Last updated: May 16, 2009
Last verified: September 2007

May 9, 2009
May 16, 2009
July 2007
Not Provided
  • Mean scores for VEGFb and pan-VEGF gene expression by IHC [ Designated as safety issue: No ]
  • Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios [ Designated as safety issue: No ]
  • Gene expression as measured by tissue microarrays [ Designated as safety issue: No ]
  • Splice form expression as measured by reverse transcriptase-PCR [ Designated as safety issue: No ]
  • VEGF165b protein expression as measured by ELISA [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00897754 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.

PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

OBJECTIVES:

  • Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.

OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Colorectal Cancer
  • Genetic: gene expression analysis
  • Genetic: protein expression analysis
  • Genetic: reverse transcriptase-polymerase chain reaction
  • Other: immunoenzyme technique
  • Other: immunohistochemistry staining method
  • Other: immunologic technique
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
200
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum

    • Receiving bevacizumab on clinical trial E-3200

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00897754
CDR0000560986, ECOG-E3200T2
Not Provided
Not Provided
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Study Chair: David Bates, PhD Bristol Heart Institute at University of Bristol
National Cancer Institute (NCI)
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP